[{"from": "human", "value": "What can you tell me about this molecule? [C][C][Branch1][C][C][C][O][C][=Branch1][C][=O][O][C][N][C][=Branch1][C][=O][C][N][Branch1][=Branch1][C][C][Ring1][#Branch1][=O][C][C][N][C][C][=Branch1][C][=O][N][Branch1][Branch2][C][=Branch1][C][=O][C][Ring1][Branch2][C][O][C][=Branch1][C][=O][O][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is the orally available active prodrug of ICRF-154, a bisdioxopiperazine derivative, with cardioprotective and antineoplastic activities. Like other ICRF compounds, sobuzoxane and its active metabolite ICRF-154 interfere with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition. Furthermore, sobuzoxane chelates metal cations thereby limiting the formation of free radical-generating anthracycline-metal complexes and may prevent anthracycline-induced oxidative damage to cardiac and soft tissues."}]